Growth Metrics

Biogen (BIIB) Total Current Liabilities (2016 - 2026)

Biogen has reported Total Current Liabilities over the past 18 years, most recently at $3.0 billion for Q1 2026.

  • For Q1 2026, Total Current Liabilities fell 43.39% year-over-year to $3.0 billion; the TTM value through Mar 2026 reached $3.0 billion, down 43.39%, while the annual FY2025 figure was $3.3 billion, 39.42% down from the prior year.
  • Total Current Liabilities for Q1 2026 was $3.0 billion at Biogen, down from $3.3 billion in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $5.5 billion in Q4 2024 and troughed at $3.0 billion in Q1 2026.
  • A 5-year average of $3.9 billion and a median of $3.3 billion in 2025 define the central range for Total Current Liabilities.
  • Biggest five-year swings in Total Current Liabilities: skyrocketed 64.37% in 2025 and later tumbled 43.39% in 2026.
  • Year by year, Total Current Liabilities stood at $3.3 billion in 2022, then grew by 4.93% to $3.4 billion in 2023, then soared by 60.99% to $5.5 billion in 2024, then crashed by 39.42% to $3.3 billion in 2025, then dropped by 10.46% to $3.0 billion in 2026.
  • Business Quant data shows Total Current Liabilities for BIIB at $3.0 billion in Q1 2026, $3.3 billion in Q4 2025, and $3.3 billion in Q3 2025.